Stock Analiz

Genmab A (GMAB) financials: revenue, earnings and cash flow

Fiscal 2017–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Genmab A’s revenue went from $381M in fiscal 2017 to $3.7B in fiscal 2025, growth of about 33.0% a year.

Net income in fiscal 2025 was $963M, a net margin of 25.9%; the best year in this period was 2024 with $1.1B.

Over the twelve months to September 30, 2026, revenue was $4.3B and net income $729M.

Free cash flow was $1.1B in fiscal 2025 and positive in 3 of the 6 years shown.

Revenue, profit and cash flow by year

Revenue
2017: $381M20172018: $464M20182019: $807M20192023: $2.4B20232024: $3.1B20242025: $3.7B2025$3.7B
Net income
2023: $631M20232024: $1.1B20242025: $963M2025$963M
Free cash flow
2023: $1.0B20232024: $1.1B20242025: $1.1B2025$1.1B
EPS (diluted)
2023: $1.0120232024: $1.8220242025: $1.542025$1.54

Income statement

Fiscal yearTTM202520242023201920182017
Revenue$4.3B$3.7B$3.1B$2.4B$807M$464M$381M
Gross profit—$3.5B$3.0B$2.4B———
Operating income—$1.1B$972M$772M———
Net income$729M$963M$1.1B$631M———
EPS (diluted)$1.17$1.54$1.82$1.01———
R&D———————
Revenue growth—+19.2%+30.6%+196.2%+74.0%+21.8%—

Cash flow

Fiscal yearTTM202520242023201920182017
Operating cash flow$875M$1.2B$1.1B$1.1B———
Capital spending-$32M-$37M-$27M-$53M———
Free cash flow$843M$1.1B$1.1B$1.0B———
Dividends paid—$0$0$0———
Buybacks———————
Stock-based pay—$128M$105M$85M———

Balance sheet

Fiscal yearTTM202520242023201920182017
Cash—$1.7B$1.4B$2.2B———
Debt—$5.3B$0$0———
Equity—$5.8B$5.1B$4.7B———
Total assets—$12.9B$6.4B$5.2B———
Shares (diluted)624M624M624M624M624M624M624M

Margins and returns

Fiscal yearTTM202520242023201920182017
Gross margin—93.6%95.4%98.6%———
Operating margin—28.6%31.1%32.3%———
Net margin17.0%25.9%36.3%26.4%———
FCF margin19.6%30.9%35.2%42.6%———
ROIC—7.7%16.2%12.7%———
ROE—16.5%22.1%13.5%———

Frequently asked questions

What is Genmab A’s annual revenue?

$3.7B in fiscal 2025 and $4.3B over the twelve months to September 30, 2026.

How much profit does Genmab A make?

Net income was $963M in fiscal 2025 (net margin 25.9%).

Is Genmab A’s revenue growing?

Yes: revenue rose 19.2% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.